查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1923003

放射性藥物療法市場（按治療方法、放射性同位素、適應症、最終用戶和分銷管道分類）—2026-2032年全球預測

Radiopharmaceutical Therapy Market by Therapy Type, Radioisotope, Indication, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，放射性藥物治療市場規模將達到 91.8 億美元，到 2026 年將成長至 99.7 億美元，複合年成長率為 10.55%，到 2032 年將達到 185.2 億美元。

關鍵市場統計數據
基準年 2025 91.8億美元
預計年份：2026年 99.7億美元
預測年份 2032 185.2億美元
複合年成長率 (%) 10.55%

權威的放射性藥物治療指南，涵蓋臨床進展、營運現狀以及面向整個醫療保健生態系統相關人員的策略重點。

放射性藥物療法已從一種小眾臨床手段轉變為重塑腫瘤學和標靶疾病管理的關鍵治療方法。過去十年，精準醫學的進步、診斷影像技術的改進以及放射性同位素生產技術的進步，共同推動了治療性放射性藥物從實驗性工具發展成為複雜適應症的臨床檢驗治療方案。這項發展體現在劑量測定技術的改進、伴隨診斷在患者選擇方面的應用，以及治療工具庫的擴展（包括α和BETA發射體療法）。臨床醫生和醫療系統日益認知到，這些藥物並非只是挽救性療法，而是多方面治療路徑中不可或缺的一部分。

對將重塑放射性藥物療法並加速臨床整合的關鍵科學、監管和營運轉折點進行全面分析

放射性藥物治療領域正經歷著由科學突破、監管發展和基礎設施日益成熟的推動而發生的變革。關鍵的技術轉折點包括α發射體療法的成熟，例如人們對錒-225類化合物的興趣重燃，以及鐳-223的新適應症的出現。這些藥物具有更高的線性能量傳遞速率和靶向細胞毒性，並可能克服一些BETA發射體療法的抗藥性。同時，碘-131、鎦-177和釔-90等BETA發射體療法也持續受益於標靶化配體的改進和劑量管理的最佳化，從而實現了更安全的門診給藥，並能更廣泛地應用於早期治療階段。

評估2025年貿易政策調整對放射性藥物治療的供應安全、商業策略和取得途徑的多層次影響

2025年美國關稅政策對整個放射性藥物治療價值鏈產生了複雜而多方面的影響，遠非簡單的成本調整所能涵蓋。在營運層面，對專用設備、前驅化學品以及放射性藥物生產中某些組件的進口關稅上調，推高了成品治療藥物和關鍵原料的到岸成本。此舉對缺乏採購規模以消化額外關稅的中小型製造商和學術創業公司影響尤為顯著，可能導致早期臨床項目延期，並減少進入後期臨床試驗的在臨床實驗藥物種類。同時，依賴跨境原料和生產設備運輸的同位素供應商也面臨利潤空間壓縮，並需要與國際合作夥伴重新談判商業條款。

可操作的細分洞察表明，不同的治療方法類型、同位素、臨床適應症、終端使用者能力和分銷模式會產生不同的策略要務。

詳細的市場細分揭示了不同治療方法類型、放射性同位素、適應症、最終用戶和分銷管道所帶來的獨特機會和營運重點。依治療方法類型分類，市場可分為α發射體治療及BETA發射體治療。 α發射體治療包括錒-225和鐳-223，它們在治療微轉移性疾病和難治性腫瘤方面顯示出良好的徵兆。另一方面，BETA發射體治療包括碘-131、鎦-177和釔-90，它們在已確立的適應症和成熟的臨床通訊協定中佔據基礎地位。以放射性同位素分類的市場結構包括錒-225、碘-131、鎦-177、鐳-223和釔-90，每種放射性同位素都有其獨特的生產、處理和劑量測定要求，這些要求會影響生產投資和臨床工作流程。就適應症而言，骨轉移、神經內分泌腫瘤、前列腺癌和甲狀腺癌是主要的臨床目標，而差異化的患者路徑和證據生成的需求正在影響著該療法的推廣速度。

區域策略資訊：說明美洲、歐洲、中東和非洲以及亞太地區的趨勢將如何影響放射性藥物療法的採用、生產和取得。

區域趨勢對全球臨床應用、生產策略和監管方式具有決定性影響。在美洲，某些市場先進的報銷體系、能夠支持複雜劑量測定和住院服務的龐大醫院網路，以及對國內同位素生產的集中投資，正在推動臨床應用。這些因素共同為高度複雜治療方法的早期商業化創造了有利環境，而支付方的審查和區域採購慣例則影響著應用順序和定價策略。歐洲、中東和非洲地區的監管環境複雜多元，既有集中監管途徑，也有國家層級的資金決策。雖然一些歐洲國家擁有強大的製造群和成熟的核醫學專業知識，但預算限制和不同的衛生技術評估要求可能導致醫療服務取得不均衡。同時，中東地區正在加大對卓越醫療中心的投資，以吸引跨國患者，而非洲部分地區基礎設施和人力資源的匱乏則限制了短期內的應用。

贊助商、同位素生產商、合約研發生產機構 (CDMO) 和臨床創新者之間的競爭與合作策略，定義了放射性藥物治療領域的競爭優勢。

產業相關人員正採取多元化的策略性舉措，以鞏固其在放射性藥物治療領域的主導地位，這些舉措包括整合專有技術、投資生產能力以及建立合作網路。擁有腫瘤產品組合的製藥公司正將放射性藥物候選藥物整合到廣泛的治療領域，利用其臨床試驗基礎設施加速核准核准流程，並與專業生產商簽訂許可協議以擴大供應規模。專注於同位素生產和放射化學服務的公司則正投資於產能擴張、自動化和品質體系建設，以滿足不斷變化的市場需求，並為尋求可預測供應鏈的申辦者提供承包解決方案。

為產業領導者提供切實可行的優先建議，以增強供應韌性、加快證據產生並確保放射性藥物療法的報銷途徑。

致力於將科學進步轉化為永續的臨床和商業性成功的領導者應採取一系列切實有效的行動。首先，優先考慮供應鏈的韌性，並考慮實現同位素來源多元化、評估區域生產夥伴關係，以及比較近岸外包與長期供應協議的經濟效益。其次，將臨床開發與真實世界證據的產生相結合，並設計包含標準化劑量測定、患者報告結局和衛生經濟學終點的註冊試驗，以促進與支付方的討論並加速技術應用。第三，透過針對核醫團隊的專項訓練、簡化門診診所的物流解決方案、減少醫院行政管理摩擦的服務模式，加強對終端用戶的支持力道。

報告的基本調查方法採用了一種透明、多方面的方法，結合了專家訪談、技術檢驗、情境分析和監管審查，旨在得出切實可行的結論。

本報告的研究採用了多源三角驗證調查方法，旨在確保研究結果的有效性、相關性和可操作性。主要資料來源包括對醫院系統臨床研究人員、生產專家、監管顧問和採購人員的結構化訪談，以了解實際營運和策略意圖。二級資訊來源資訊來源同行評審文獻、臨床試驗註冊資訊、監管指導文件、生產白皮書和上市公司披露資訊，以提供背景資訊和佐證細節。技術論證則透過諮詢劑量學專家和放射化學從業人員獲得，以確保操作建議符合當前的最佳實踐。

本文簡明扼要地總結了放射性藥物治療這一不斷發展的領域中，定義成功的臨床預期、營運挑戰和策略重點。

放射性藥物療法正處於一個轉折點，科學進步、基礎設施投資和政策變革相互作用，既帶來了巨大的機遇，也帶來了巨大的風險。臨床進展，特別是α發射體和精準靶向BETA發射體的進展，正在拓展骨轉移、神經內分泌腫瘤、前列腺癌和甲狀腺癌等適應症的治療選擇。然而，要充分發揮這些潛力，需要實際解決供應鏈複雜性、生產規模擴大和支付方接受度等挑戰。預計2025年實施的關稅主導環境，將透過重塑成本結構和推動生產及分銷的策略調整，進一步加速這些趨勢的發展。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依治療方法的放射性藥物治療市場

  • α粒子療法
    • 錒-225
    • 鐳-223
  • BETA射線療法
    • 碘-131
    • 鎦-177
    • 釔-90

9. 按放射性同位素分類的放射性藥物治療市場

  • 錒-225
  • 碘-131
  • 鎦-177
  • 鐳-223
  • 釔-90

第10章 依適應症分類的放射性藥物治療市場

  • 骨轉移
  • 神經內分泌腫瘤
  • 攝護腺癌
  • 甲狀腺癌

第11章 依最終用戶分類的放射性藥物治療市場

  • 醫院
  • 研究所
  • 專科診所

第12章 放射性藥物治療市場（依分銷管道分類）

  • 離線
  • 線上

第13章 放射性藥物治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 放射性藥物治療市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國放射性藥物治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國放射性藥物治療市場

第17章：中國放射性藥物治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Actinium Pharmaceuticals, Inc.
  • AdvanCell Isotopes Pty Ltd.
  • Aktis Oncology Inc.
  • Alpha Tau Medical Ltd.
  • Ariceum Therapeutics GmbH
  • ARTBIO Inc.
  • Bayer AG
  • Blue Earth Therapeutics Ltd.
  • BWXT Medical Ltd.
  • Cellectar Biosciences, Inc.
  • Clarity Pharmaceuticals Ltd.
  • Convergent Therapeutics, Inc.
  • Eckert & Ziegler AG
  • Eli Lilly and Company
  • Full-Life Technologies Ltd.
  • Fusion Pharmaceuticals Inc.
  • GE HealthCare Technologies Inc.
  • Jubilant Pharmova Limited
  • Lantheus Holdings, Inc.
  • Novartis AG
  • Oncoinvent ASA
  • Perspective Therapeutics Inc.
Product Code: MRR-867BED9A9EB9

The Radiopharmaceutical Therapy Market was valued at USD 9.18 billion in 2025 and is projected to grow to USD 9.97 billion in 2026, with a CAGR of 10.55%, reaching USD 18.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.18 billion
Estimated Year [2026] USD 9.97 billion
Forecast Year [2032] USD 18.52 billion
CAGR (%) 10.55%

An authoritative orientation to radiopharmaceutical therapy that frames clinical advances, operational realities, and strategic priorities for stakeholders across the healthcare ecosystem

Radiopharmaceutical therapy has transitioned from a niche clinical approach into a pivotal modality reshaping oncology and targeted disease management. Over the past decade, the convergence of precision medicine, improved imaging modalities, and advances in radioisotope production has elevated therapeutic radiopharmaceuticals from experimental tools into clinically validated options for complex indications. This evolution reflects improvements in dosimetry, patient selection using companion diagnostics, and an expanding therapeutic toolkit that includes both alpha and beta emitter therapies. Clinicians and health systems are increasingly viewing these agents not only as salvage therapies but as integral components of multimodal care pathways.

The clinical promise is matched by a material transformation across the ecosystem that includes manufacturers, contract development and manufacturing organizations, isotope suppliers, regulatory bodies, and payers. Innovations in generator technologies and centralized production have addressed some historical bottlenecks, while increased commercial interest has driven investment into new isotopes and delivery systems. At the same time, constraints remain: complex logistics, stringent cold chain requirements, specialized workforce needs, and evolving reimbursement frameworks all affect uptake. Stakeholders who understand these operational dynamics and the interplay between clinical evidence generation and commercialization will be best positioned to translate scientific progress into accessible therapies for patients. As a result, decision-makers must align clinical development with pragmatic manufacturing and distribution strategies to realize the full potential of radiopharmaceutical therapy.

Comprehensive analysis of the major scientific, regulatory, and operational inflection points reshaping radiopharmaceutical therapy and accelerating clinical integration

The landscape of radiopharmaceutical therapy is undergoing transformative shifts driven by scientific breakthroughs, regulatory momentum, and infrastructural maturation. A major technical shift is the maturation of alpha emitter therapies, exemplified by renewed interest in actinium-225-based compounds and renewed applications for radium-223, which offer higher linear energy transfer and targeted cytotoxicity that can overcome some forms of resistance to beta emitters. Concurrently, beta emitter therapies such as iodine-131, lutetium-177, and yttrium-90 continue to benefit from improved targeting ligands and better dosimetric control, enabling safer outpatient administration and broader integration into earlier lines of therapy.

Parallel to therapeutic innovations are changes in how therapies are developed and delivered. Theranostic paradigms that pair diagnostic imaging with therapeutic agents are accelerating patient selection and adaptive dosing strategies, while standardized dosimetry is gaining traction as a tool to individualize treatment and enhance safety. On the manufacturing front, investments in domestic isotope production capacity, cold-chain logistics, and automated radiochemistry platforms are reshaping supply assurance and reducing cycle times. Regulatory agencies in multiple jurisdictions are also adapting, with clearer pathways for accelerated approvals and conditional access where unmet need and robust biomarker-driven evidence exist. Finally, collaborative models between industry, academic centers, and specialized clinics are broadening clinical trial access and enabling pragmatic data collection. Taken together, these shifts point toward a future where radiopharmaceutical therapy is more precise, more accessible, and embedded within personalized oncology strategies.

Assessment of the multi-layered consequences of 2025 trade policy adjustments on supply stability, commercial strategies, and access pathways for radiopharmaceutical therapies

The introduction of United States tariffs in 2025 has created a complex, multi-dimensional impact across the radiopharmaceutical therapy value chain that extends beyond simple cost adjustments. At the operational level, higher import duties on specialized equipment, precursor chemicals, and certain components of radiopharmaceutical production elevate the landed cost of both finished therapies and critical inputs. This dynamic disproportionately affects smaller manufacturers and academic spinouts that lack the purchasing scale to absorb incremental tariffs, potentially slowing early-stage clinical programs and reducing the diversity of investigational products entering late-stage trials. In parallel, isotope suppliers reliant on cross-border shipments for feedstock or production apparatus face tighter margins and the need to renegotiate commercial terms with international partners.

Strategically, the tariffs have accelerated discussions about nearshoring and vertical integration among firms that view supply stability as mission critical. Companies are evaluating whether to invest in domestic cyclotron and generator capacity, localized radiochemistry facilities, and redundant supply routes to mitigate trade exposure. While capital-intensive, such investments can improve control over schedules and quality assurance. However, these shifts also create barriers to entry for new innovators, concentrate production in larger vertically integrated players, and risk reducing competitive pricing pressure over time. Clinically, the effects may be felt in procurement cycles at hospitals and specialty clinics, where tighter budgets prompt prioritization of therapies with clearer cost-effectiveness profiles. Payers and health systems are responding by tightening formulary pathways, demanding stronger real-world evidence for value, and seeking outcome-based contracting models. Ultimately, the 2025 tariff environment underscores the need for adaptive commercial models, diversified sourcing strategies, and collaborative public-private solutions to sustain the momentum of therapeutic innovation while protecting patient access.

Actionable segmentation insights revealing how therapy types, isotopes, clinical indications, end-user capabilities, and distribution models create distinct strategic imperatives

Granular segmentation reveals differentiated opportunities and operational priorities across therapy types, radioisotopes, indications, end users, and distribution channels. Based on therapy type, the market divides into alpha emitter therapy and beta emitter therapy, where alpha emitter therapy includes actinium-225 and radium-223 and offers compelling efficacy signals for micrometastatic disease and refractory tumors, while beta emitter therapy includes iodine-131, lutetium-177, and yttrium-90 and remains foundational for established indications with mature clinical protocols. Based on radioisotope, the landscape comprises actinium-225, iodine-131, lutetium-177, radium-223, and yttrium-90, each with unique production, handling, and dosimetric requirements that influence manufacturing investments and clinical workflows. For indications, the principal clinical targets are bone metastases, neuroendocrine tumors, prostate cancer, and thyroid cancer, with differentiated patient pathways and evidence-generation needs shaping adoption velocity.

End users span hospitals, research institutes, and specialty clinics, and each setting has distinct operational capabilities: hospitals often provide integrated oncology and nuclear medicine services with complex inpatient support; research institutes drive early-phase trials and translational science; and specialty clinics focus on streamlined outpatient delivery models that require optimized logistics and reimbursement navigation. Distribution channels include direct sales, distributors, and online pharmacies, and channel strategy affects lead times, cold-chain integrity, and margin structures. Taken together, these segmentations imply that successful commercial approaches will be those that align isotope selection with indication-specific clinical evidence, match manufacturing and distribution models to end-user capabilities, and tailor commercial outreach to the procurement preferences of hospitals versus specialty clinics. Pragmatic segmentation-driven portfolio planning and targeted investments in clinician education and logistics will therefore determine which programs scale most rapidly.

Regional strategic intelligence that explains how Americas, Europe, Middle East & Africa, and Asia-Pacific dynamics shape adoption, manufacturing, and access for radiopharmaceutical therapies

Regional dynamics exert a decisive influence on clinical adoption, manufacturing strategy, and regulatory approaches across the globe. In the Americas, clinical uptake is driven by advanced reimbursement frameworks in select markets, an extensive hospital network capable of supporting complex dosimetry and inpatient services, and concentrated investment in domestic isotope production. These factors combine to create an environment favorable to early commercialization of high-complexity therapies, though payer scrutiny and regional procurement practices shape launch sequencing and pricing strategies. Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where centralized regulatory pathways coexist with country-level funding decisions; several European nations have strong manufacturing clusters and established nuclear medicine expertise, yet access can be uneven due to budgetary constraints and divergent health-technology assessment requirements. In contrast, the Middle East shows growing investment in centers of excellence that aim to attract cross-border patients, while parts of Africa face infrastructure and workforce gaps that limit near-term adoption.

Asia-Pacific is characterized by rapid clinical expansion in selected markets, growing investment in cyclotron and isotope production capacity, and regulatory systems that are progressively clarifying pathways for theranostic agents. However, differences in healthcare financing, distribution infrastructure, and local manufacturing capabilities mean that strategies successful in one APAC market may not translate directly to others. Across all regions, barriers such as cold-chain logistics, workforce specialization, and local regulatory harmonization remain common constraints, while regional strengths in clinical expertise, patient volumes, or manufacturing capacity create differentiated opportunities for targeted investment and partnership models.

Competitive and collaborative strategies across sponsors, isotope producers, CDMOs, and clinical innovators that define competitive advantage in radiopharmaceutical therapy

Industry players are pursuing diverse strategic pathways to secure leadership positions in radiopharmaceutical therapy, blending proprietary science with capacity investments and collaborative networks. Pharmaceutical sponsors with oncology portfolios are integrating radiopharmaceutical candidates into broader therapeutic franchises, leveraging clinical trial infrastructures to accelerate registrational programs and forging licensing agreements with specialized manufacturers to scale supply. Companies focused on isotope production and radiochemistry services are investing in capacity expansion, automation, and quality systems to meet evolving demand and to provide turnkey solutions for sponsors seeking predictable supply chains.

At the same time, a range of smaller biotech firms and academic spinouts are differentiating through novel targeting ligands, enhanced chelation chemistry, and improved dosimetry approaches; these entities often rely on strategic partnerships with larger firms for late-stage development and commercialization. Contract manufacturers and logistics specialists are sharpening their value propositions by certifying regulatory compliance, optimizing cold-chain protocols, and developing satellite production models that shorten lead times. Across the ecosystem, competitive advantage increasingly hinges on the ability to demonstrate integrated capabilities: reliable isotope sourcing, repeatable manufacturing workflows, and robust clinical data generation that supports payer conversations. Strategic M&A, capacity-sharing consortia, and public-private partnerships are likely to continue shaping the competitive landscape as firms seek to secure both supply resilience and clinical leadership.

Practical and prioritized recommendations for industry leaders to build supply resilience, accelerate evidence generation, and secure reimbursement pathways for radiopharmaceutical therapies

Leaders seeking to translate scientific progress into sustainable clinical and commercial success should pursue a set of pragmatic, high-impact actions. First, prioritize supply resilience by diversifying isotope sourcing, evaluating regional production partnerships, and assessing the economics of nearshoring versus long-term supplier agreements. Second, align clinical development with real-world evidence generation by designing registrational trials that incorporate standardized dosimetry, patient-reported outcomes, and health-economic endpoints to ease payer discussions and accelerate adoption. Third, invest in end-user enablement through targeted education for nuclear medicine teams, streamlined logistics solutions for outpatient clinics, and service models that reduce administrative friction for hospitals.

Fourth, engage proactively with regulators and health-technology assessment bodies to define acceptable evidence packages and to explore conditional-access pathways where unmet need is high. Fifth, adopt flexible commercial models that include value-based contracting or outcomes-linked agreements to mitigate reimbursement risk and demonstrate long-term value. Sixth, expand internal capabilities in radiochemistry automation, quality systems, and digital tracking to reduce cycle times and ensure compliance across jurisdictions. Finally, cultivate strategic alliances with academic centers and specialized clinics to accelerate clinical validation, broaden trial access, and build the real-world datasets necessary for payer acceptance. Executed cohesively, these measures will enable organizations to capture clinical upside while managing operational and commercial risk in an evolving policy and supply environment.

Transparent, multi-source research methodology combining expert interviews, technical validation, scenario analysis, and regulatory review to support actionable conclusions

The research underpinning this report synthesizes a multi-source, triangulated methodology designed to ensure validity, relevance, and actionable insight. Primary inputs included structured interviews with clinical investigators, manufacturing experts, regulatory advisers, and procurement leads at hospital systems to capture operational realities and strategic intent. Secondary sources comprised peer-reviewed literature, clinical trial registries, regulatory guidance documents, manufacturing white papers, and open-source company disclosures to provide context and corroborative detail. Technical validation was achieved through consultation with dosimetry specialists and radiochemistry practitioners to ensure that operational recommendations reflect current best practices.

Analytical methods combined qualitative thematic analysis with scenario-based assessments to explore how variables such as supply constraints, trade policy shifts, and reimbursement changes could influence strategic outcomes. Where appropriate, sensitivity analyses were used to stress-test assumptions related to production lead times, clinical adoption rates, and distribution complexity. The research team also conducted a review of relevant patent landscapes and collaboration networks to map capability clusters and potential partnership pathways. Limitations include variability in national regulatory implementations and the evolving nature of early clinical data for emerging alpha-emitter therapies; these uncertainties were addressed by presenting multiple scenarios and flagging areas where ongoing data collection is required. The overall approach emphasizes transparency, repeatable methods, and collaboration with domain experts to produce findings that are both credible and practicable.

Concise synthesis of clinical promise, operational challenges, and strategic priorities that define success in the evolving radiopharmaceutical therapy landscape

Radiopharmaceutical therapy stands at an inflection point where scientific momentum, infrastructural investment, and evolving policy interact to create both substantive opportunity and meaningful risk. Clinical advances-particularly in alpha emitter agents and precision-targeted beta emitters-are expanding therapeutic options for indications such as bone metastases, neuroendocrine tumors, prostate cancer, and thyroid cancer. Yet the realization of that promise depends on pragmatic solutions to supply-chain complexity, manufacturing scale-up, and payer acceptance. The tariff-driven environment introduced in 2025 amplifies these dynamics by reshaping cost structures and incentivizing strategic reconfiguration of production and distribution.

For stakeholders, the imperative is clear: align clinical development with durable operational models, invest in supply resilience, and produce the real-world evidence necessary to secure reimbursement and sustained patient access. Organizations that proactively address workforce development, regulatory engagement, and manufacturing agility will not only navigate near-term headwinds but will also establish durable competitive advantages. In sum, radiopharmaceutical therapy is poised to become an increasingly mainstream element of precision oncology, but success will require integrated strategies that bridge science, supply, and commercialization.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Radiopharmaceutical Therapy Market, by Therapy Type

  • 8.1. Alpha Emitter Therapy
    • 8.1.1. Actinium-225
    • 8.1.2. Radium-223
  • 8.2. Beta Emitter Therapy
    • 8.2.1. Iodine-131
    • 8.2.2. Lutetium-177
    • 8.2.3. Yttrium-90

9. Radiopharmaceutical Therapy Market, by Radioisotope

  • 9.1. Actinium-225
  • 9.2. Iodine-131
  • 9.3. Lutetium-177
  • 9.4. Radium-223
  • 9.5. Yttrium-90

10. Radiopharmaceutical Therapy Market, by Indication

  • 10.1. Bone Metastases
  • 10.2. Neuroendocrine Tumors
  • 10.3. Prostate Cancer
  • 10.4. Thyroid Cancer

11. Radiopharmaceutical Therapy Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Radiopharmaceutical Therapy Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Radiopharmaceutical Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Radiopharmaceutical Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Radiopharmaceutical Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Radiopharmaceutical Therapy Market

17. China Radiopharmaceutical Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Actinium Pharmaceuticals, Inc.
  • 18.6. AdvanCell Isotopes Pty Ltd.
  • 18.7. Aktis Oncology Inc.
  • 18.8. Alpha Tau Medical Ltd.
  • 18.9. Ariceum Therapeutics GmbH
  • 18.10. ARTBIO Inc.
  • 18.11. Bayer AG
  • 18.12. Blue Earth Therapeutics Ltd.
  • 18.13. BWXT Medical Ltd.
  • 18.14. Cellectar Biosciences, Inc.
  • 18.15. Clarity Pharmaceuticals Ltd.
  • 18.16. Convergent Therapeutics, Inc.
  • 18.17. Eckert & Ziegler AG
  • 18.18. Eli Lilly and Company
  • 18.19. Full-Life Technologies Ltd.
  • 18.20. Fusion Pharmaceuticals Inc.
  • 18.21. GE HealthCare Technologies Inc.
  • 18.22. Jubilant Pharmova Limited
  • 18.23. Lantheus Holdings, Inc.
  • 18.24. Novartis AG
  • 18.25. Oncoinvent ASA
  • 18.26. Perspective Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ACTINIUM-225, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY IODINE-131, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY LUTETIUM-177, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIUM-223, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY YTTRIUM-90, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BONE METASTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BONE METASTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BONE METASTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY NEUROENDOCRINE TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THYROID CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THYROID CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GCC RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 176. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. G7 RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY ALPHA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY BETA EMITTER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY RADIOISOTOPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA RADIOPHARMACEUTICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)